Back to Search
Start Over
Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose.
- Source :
-
Le infezioni in medicina [Infez Med] 2012 Dec; Vol. 20 (4), pp. 293-5. - Publication Year :
- 2012
-
Abstract
- We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, naïve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.
- Subjects :
- Adult
Anti-HIV Agents pharmacology
Atazanavir Sulfate
Female
HIV Infections
Humans
Male
Middle Aged
Oligopeptides pharmacology
Pyridines pharmacology
Viral Load drug effects
Anti-HIV Agents administration & dosage
Anti-HIV Agents pharmacokinetics
Oligopeptides administration & dosage
Oligopeptides pharmacokinetics
Pyridines administration & dosage
Pyridines pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 2532-8689
- Volume :
- 20
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Le infezioni in medicina
- Publication Type :
- Editorial & Opinion
- Accession number :
- 23299071